$AVAC

American Ventures Acquisition Corp. I

Insider trades
0
0
1

No SEC Form 4 filings for $AVAC in the last 30 days.

See all $AVAC insider activity →
High

Drug Trial Data Manipulation Wiped Avacopan’s EU Approval as FDA Hearing Looms

The EMA published an Aug 6, 2026 assessment report detailing alleged manipulation of nine patient records in the ADVOCATE Phase 3 trial of avacopan (Tavneos), after database lock and unblinding. The European Commission revoked EU approval Aug 6, 2026, following a June 25 CHMP recommendation. In the US, the FDA is reviewing Amgen’s July 23 hearing submission to withdraw Tavneos, based on similar data-integrity issues.

AVAC sentiment & insider activity

Over the past 7 days, alphai's AI scored 1 news story mentioning AVAC (American Ventures Acquisition Corp. I). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.

What's driving AVAC

  • EU withdrawal and an FDA hearing proposal increase the probability of US label withdrawal or major restriction for avacopan/Tavneos.

    techtimes.com · Aug 14, 2026

alphai scores every news story that mentions AVAC with an AI model for sentiment and relevance, and aggregates insider trades from American Ventures Acquisition Corp. I's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AVAC

Score
$AVACHighAI 9/10

Drug Trial Data Manipulation Wiped Avacopan’s EU Approval as FDA Hearing Looms

The EMA published an Aug 6, 2026 assessment report detailing alleged manipulation of nine patient records in the ADVOCATE Phase 3 trial of avacopan (Tavneos), after database lock and unblinding. The European Commission revoked EU approval Aug 6, 2026, following a June 25 CHMP recommendation. In the US, the FDA is reviewing Amgen’s July 23 hearing submission to withdraw Tavneos, based on similar data-integrity issues.